Should and Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?
作者信息
Baud Frédéric J, Houzé Pascal
机构信息
Assistance Publique - Hopitaux de Paris, Paris, France
出版信息
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00388-20.
Abstract
摘要
相似文献
1
Should and Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?连续性肾脏替代治疗期间抗菌药物的应用及研究是否应遵循药代动力学的一般原则？
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00388-20.
2
Reply to Baud and Houzé, "Should and Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?".对博德和胡泽的回复：“连续性肾脏替代治疗期间抗菌药物的研究是否应遵循药代动力学的一般原则？”
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00401-20.
3
Antimicrobial Disposition During Pediatric Continuous Renal Replacement Therapy Using an Ex Vivo Model.儿科连续性肾脏替代治疗中应用体外模型的抗菌药物处置。
Crit Care Med. 2019 Sep;47(9):e767-e773. doi: 10.1097/CCM.0000000000003895.
4
Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.接受肾脏替代治疗患者抗菌治疗的药代动力学考量
Clin Pharmacokinet. 2007;46(12):997-1038. doi: 10.2165/00003088-200746120-00003.
5
Does Pharmacokinetics in the Central Compartment Evidence Routes of Elimination During Continuous Renal Replacement Therapy in Ex Vivo Model?在体外模型中，持续肾脏替代治疗期间中央室的药代动力学能否证明消除途径？
Crit Care Med. 2020 Feb;48(2):e163-e164. doi: 10.1097/CCM.0000000000004036.
6
Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.儿童连续肾脏替代治疗中常用药物的药代动力学：当前文献的系统评价。
Clin Pharmacokinet. 2022 Feb;61(2):189-229. doi: 10.1007/s40262-021-01085-z. Epub 2021 Nov 30.
7
Anti-infective prescribing practices in critically ill children on continuous renal replacement therapy: a multicenter survey of French-speaking countries.连续性肾脏替代治疗危重症儿童的抗感染药物处方实践：法语国家的多中心调查。
J Nephrol. 2023 Dec;36(9):2541-2547. doi: 10.1007/s40620-023-01762-1. Epub 2023 Sep 12.
8
Practical considerations for individualizing drug dosing in critically ill adults receiving renal replacement therapy.在接受肾脏替代治疗的重症成年患者中实现个体化给药的实际考量
Pharmacotherapy. 2023 Nov;43(11):1194-1205. doi: 10.1002/phar.2858. Epub 2023 Aug 1.
9
Pharmacokinetics and antimicrobial dosing adjustment in critically ill patients during continuous renal replacement therapy.危重症患者持续肾脏替代治疗期间的药代动力学及抗菌药物剂量调整
Clin Nephrol. 2007 May;67(5):267-84. doi: 10.5414/cnp67267.
10
Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy.应用药代动力学/药效学原理优化连续性肾脏替代治疗期间的抗菌治疗。
Anaesthesiol Intensive Ther. 2017;49(5):412-418. doi: 10.5603/AIT.a2017.0071. Epub 2017 Nov 24.
引用本文的文献
1
Edoxaban pharmacokinetics during in vitro continuous renal replacement therapy.依度沙班在体外持续肾脏替代治疗期间的药代动力学。
BMC Nephrol. 2024 Oct 10;25(1):341. doi: 10.1186/s12882-024-03777-7.
2
Vancomycin Sequestration in ST Filters: An In Vitro Study.万古霉素在ST过滤器中的潴留：一项体外研究
Antibiotics (Basel). 2023 Mar 21;12(3):620. doi: 10.3390/antibiotics12030620.
3
Reply to Baud and Houzé, "Should and Studies on Antimicrobial Agents during Continuous Renal Replacement Therapy Comply with General Principles of Pharmacokinetics?".对博德和胡泽的回复：“连续性肾脏替代治疗期间抗菌药物的研究是否应遵循药代动力学的一般原则？”
Antimicrob Agents Chemother. 2020 May 21;64(6). doi: 10.1128/AAC.00401-20.
本文引用的文献
1
Diafiltration flowrate is a determinant of the extent of adsorption of amikacin in renal replacement therapy using the ST150-AN69 filter: An in vitro study.透析液流量是 ST150-AN69 过滤器行肾脏替代治疗时阿米卡星吸附程度的决定因素：一项体外研究。
Int J Artif Organs. 2020 Dec;43(12):758-766. doi: 10.1177/0391398820911928. Epub 2020 May 1.
2
Does Pharmacokinetics in the Central Compartment Evidence Routes of Elimination During Continuous Renal Replacement Therapy in Ex Vivo Model?在体外模型中，持续肾脏替代治疗期间中央室的药代动力学能否证明消除途径？
Crit Care Med. 2020 Feb;48(2):e163-e164. doi: 10.1097/CCM.0000000000004036.
3
Pharmacokinetics and Dialytic Clearance of Isavuconazole During In Vitro and In Vivo Continuous Renal Replacement Therapy.体外和体内连续性肾脏替代治疗期间艾沙康唑的药代动力学和透析清除率
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01085-19. Epub 2019 Sep 16.
4
Antimicrobial Disposition During Pediatric Continuous Renal Replacement Therapy Using an Ex Vivo Model.儿科连续性肾脏替代治疗中应用体外模型的抗菌药物处置。
Crit Care Med. 2019 Sep;47(9):e767-e773. doi: 10.1097/CCM.0000000000003895.
5
RE to manuscript 'In vitro removal of anti-infective agents by a novel cytokine adsorbent system'.
Int J Artif Organs. 2019 Sep;42(9):528-529. doi: 10.1177/0391398819854461. Epub 2019 Jun 11.
6
Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy.连续性肾脏替代治疗期间头孢洛扎/他唑巴坦的体外清除率
Blood Purif. 2017;44(1):16-23. doi: 10.1159/000455897. Epub 2017 Feb 25.
7
The adsorption of vancomycin by polyacrylonitrile, polyamide, and polysulfone hemofilters.万古霉素在聚丙烯腈、聚酰胺和聚砜血液滤过器上的吸附作用。
Artif Organs. 2008 Jan;32(1):81-4. doi: 10.1111/j.1525-1594.2007.00460.x.
8
Adsorption of amikacin, a significant mechanism of elimination by hemofiltration.阿米卡星的吸附作用，这是血液滤过清除药物的一个重要机制。
Antimicrob Agents Chemother. 2008 Mar;52(3):1009-13. doi: 10.1128/AAC.00858-07. Epub 2007 Dec 17.
9
Aminoglycoside binding to polyacrylonitrile hemofilter membranes during continuous hemofiltration.
ASAIO Trans. 1987 Jul-Sep;33(3):300-3.
Zotero 插件